



**Report of the meeting on catalysing HIV/TB Research: innovation, funding and networking held in conjunction with the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention
Cape Town, South Africa on 18-21 July, 2009**

Making TB research a priority

"The consequences of inattention to TB research are not just embarrassing, they are tragic and shameful. Generations of research advances and technologies have bypassed the field of TB research. All of the great breakthroughs that we have seen in molecular biology - there was nobody working on it in TB.

Nine million people develop active TB each year and yet we still don't have an effective vaccine. There have been no newly licensed drugs for TB in forty years [with the exception of rifabutin]. The therapeutic regimens, although they work, are cumbersome and prone to the development of drug resistance. The diagnostics are ridiculous, they are antiquated, non-standardised and imprecise."

- Dr Tony Fauci, Director of the US National Institute of Allergy and Infectious Diseases (NIAID) at a meeting held in Cape Town just prior to IAS 2009

The World Health Organization and the TB/HIV Working Group of the Stop TB Partnership in collaboration with the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE), International AIDS Society, Treatment Action Group and the Desmond Tutu HIV Centre of University of Cape Town organized a highly visible meeting in conjunction with the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Cape Town, South Africa on 18-19 July, 2009.

The meeting was attended by some 250 HIV researchers, activists and representatives from funding agencies. The meeting focused on critical TB/HIV issues in the areas of TB prevention, diagnosis and treatment, childhood TB and drug resistant TB. New and previously unreported data was shared, discussed and research priorities were defined. The research priority discussions during the meeting also informed the on-going revision of the TB/HIV research priorities document by the World Health Organisation, which will soon be finalised. The outcome and key findings of the meeting were communicated to the IAS conference delegates through a satellite symposium on 21 July, 2009. Webcast of the satellite symposium is available at the following link:

<http://www.ias2009.org/pag/webcasts/?sessionid=2449>

Presentations

21 July, 2009

[Preventing TB in People Living with HIV: research priorities and way forward by Peter Godfrey-Faussett, UK](#)

[TB in HIV-infected Children: addressing the research neglect by Soumya Swaminathan, India](#)

[Drug resistance TB in People Living with HIV: research questions and priorities by Haileyesus Getahun, Switzerland](#)

[Clinical challenges of diagnosing and treating TB in People Living with HIV: what next for research? By Prudence Ive, South Africa](#)

19 July, 2009 - Key note presentation

[Challenges on TB-HIV Research by Françoise Barré-Sinoussi, France](#)

[Watch Dr. Barré-Sinoussi's plenary presentation](#)

[Research activism from HIV to TB by Mark Harrington, USA](#)

Session III: Childhood TB

[TB diagnosis in Children: experience with HIV-infected children by Anneke Hesseling, South Africa](#)

[ARV TB drug experience in children: when and what to start? By Philippa Musoke, Uganda](#)

[Mother to child transmission of TB: what do we know? By Amita Gupta, India](#)

[Developing safer TB vaccines for children with HIV by Jerald Sadoff, USA](#)

Session IV: Drug resistance TB and HIV

[MDR, XDR TB and HIV: global data, approaches and operational research issues by Paul Nunn, Switzerland](#)

[MDR and XDR TB in people living with HIV: what do we know and what we still need to know by Neel Gandhi, USA](#)

[Drug resistance TB and new diagnostics for people living with HIV: emerging data from FIND by Giorgio Roscigno, Switzerland](#)

[Molecular epidemiology: role for transmission of MDR/XDR by Paul van Helden, South Africa](#)

July 18, 2009 - Key note presentations

[HIV/TB overview and rationale of meeting by Diane Havlir, USA](#)

[Research on TB and HIV/AIDS: Progress and Challenges by Anthony Fauci, USA](#)

[Watch Dr. Fauci's plenary presentation](#)

Session I: Diagnosis and Treatment

[Strategies for co-treatment: first and second line ART and TB treatment by Gary](#)

[Maartens, South Africa](#)

[Role of TB in early mortality of people living with HIV by Mina Hosseinipour, Malawi](#)

Sub-clinical TB among people living with HIV: what does the evidence say? By
Haileyesus Getahun, Switzerland

[The latest developments in diagnosis and management of TB IRIS: what are the gaps? By
Graeme Meintjes, South Africa](#)

Session II: TB Prevention

Isoniazid preventive therapy: outcome of massive scale-up among miners in South Africa
by Gavin Churchyard, South Africa

[TB infection control among people living with HIV: what do we know? By Rod Escombe,
UK](#)

Impact of ART on TB Prevention by Robin Wood, South Africa

[TB diagnosis in the community: approaches and outcomes by Helen Ayles, Zambia](#)